Average Co-Inventor Count = 5.01
ph-index = 13
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. The Scripps Research Institute (50 from 1,187 patents)
2. International Aids Vaccine Initiative (20 from 69 patents)
3. Theraclone Sciences, Inc. (14 from 28 patents)
4. University of California (4 from 15,528 patents)
5. Other (3 from 832,912 patents)
6. The United States of America, as Represented by the Secretary, Department of Health and Human Services (3 from 3,540 patents)
7. Cornell University (3 from 2,886 patents)
8. The University of Texas System (1 from 5,463 patents)
9. Dennis R. Burton (0 patent)
10. James E., Jr. Crowe (0 patent)
11. Carlos F., III Barbas (0 patent)
12. Brian R. Murphy (0 patent)
13. Robert M. Chanock (0 patent)
14. Theraclone Science, Int. (0 patent)
53 patents:
1. 12410243 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
2. 12398177 - SIV envelope trimer
3. 12312396 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
4. 12241081 - B cell receptor modification in B cells
5. RE50268 - Broadly neutralizing antibody and uses thereof
6. 12018067 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
7. 11845789 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
8. 11795211 - Rapid elicitation of broadly neutralizing antibodies to HIV Env
9. 11767347 - HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion envelope conformations
10. 11584789 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
11. 11319362 - Methods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
12. RE49037 - Broadly neutralizing antibody and uses thereof
13. 11236134 - Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations
14. 10865234 - Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
15. 10836811 - Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody